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Abstract
Background: Risk stratification for patients with nonvariceal upper gastrointestinal (NVUGI) bleeding is crucial for
successful prognosis and treatment. Recently, the AIMS65 score has been used to predict mortality risk and
rebleeding. The purpose of this study was to compare the performance of the AIMS65 score with the Glasgow-
Blatchford score (GBS), Rockall score, and pre-endoscopic Rockall score in Korea.
Methods: We retrospectively studied 512 patients with NVUGI bleeding who were treated at a university hospital
between 2013 and 2016. The AIMS65, GBS, Rockall score, and pre-endoscopic Rockall score were used to stratify
patients based on their bleeding risk. The primary outcome was in-hospital mortality. The secondary outcomes
were composite clinical outcomes of mortality, rebleeding, and intensive care unit (ICU) admission. Each scoring
system was compared using the receiver-operating curve (ROC).
Results: A total of 17 patients (3.3%) died and rebleeding developed in 65 patients (12.7%). Eighty-six patients
(16.8%) required ICU admission. The AIMS65 (area under the curve (AUC) 0.84, 95% confidence interval, 0.81–0.88))
seemed to be superior to the GBS (AUC 0.72, 0.68–0.76), the Rockall score (AUC 0.75, 0.71–0.79), or the pre-
endoscopic Rockall score (AUC 0.74, 0.70–0.78) in predicting in-hospital mortality, but there was not a statistically
significant difference between the groups (P = 0.07). The AUC value of the AIMS65 was not significantly different
from the other scoring systems in prediction of rebleeding, endoscopic intervention, or ICU admission.
Conclusions: The AIMS65 score in NVUGI bleeding patients was comparable to the GBS or Rockall scoring systems
when predicting the mortality, rebleeding, or ICU admission. Because AIMS65 is a much easier, readily calculated
scoring system compared to the others, we would recommend using the AIMS65 in daily practice.
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Background
Upper gastrointestinal (UGI) bleeding is a medical emer-
gency with an incidence of mortality of 5–10% [1]. The
guidelines recommend use of risk stratification tools in
UGI bleeding to facilitate accurate triage and assist in
clinical decisions such as endoscopic timing and level of
care [2, 3]. It is important for physicians to identify UGI
bleeding patients who are at high risk of mortality or
rebleeding.
There are some scoring systems have been devel-
oped to predict bleeding outcomes for patients with
UGI bleeding. The Rockall score (RS) and the Glas-
gow-Blatchford risk score (GBS) are the most widely-
used scoring systems in clinical practice [4, 5]. These
scoring systems have been reported to be useful in
predicting mortality, rebleeding, need for transfusion,
and hemostasis [6, 7]. However, there are limitations
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in these scoring systems. The GBS is difficult to calcu-
late in routine clinical practice due to complex nature
of score calculation, and the RS requires endoscopic
findings.
Recently, much interest has been shown in pre-endo-
scopic risk scores for UGI bleeding. The pre-endoscopy
Rockall score (PRS) excludes the endoscopic findings
that are needed for the RS; because of this, using the
PRS to make clinical predictions, has been controversial
[8, 9]. The AIMS65 scoring system was developed to de-
termine the prognosis of patients with UGI bleeding
[10]. The AIMS65 score is based on albumin levels, pro-
thrombin time (PT), international normalized ratio
(INR), altered mental status, systolic blood pressure, and
whether age is 65 years and older. One point is assigned
to each variable that increases the risk of clinical out-
comes. Compared to other scoring systems, the AIMS65
has the advantage of being simple to perform in an
emergency situation [11–13]. But AIMS65 score has not
been sufficiently validated in Korea. Few studies have
compared AIMS65 score with other scoring systems [11,
14]. One study suggested that AIMS65 score was not
suitable for predicting the need for endoscopic interven-
tion [14].
The causes of UGI bleeding differ among countries.
The prevalence of variceal bleeding is higher in Korea
than in Western countries [14]. Limited data are avail-
able on validation of scoring systems in patients with
non-variceal UGI (NVUGI) bleeding in Korea.
The aim of this study was to compare the predictive
value of the AIMS65 with the GBS, PRS, and RS scores
for a large scale of NVUGI bleeding patients in Korea.
Methods
Inclusion and exclusion criteria of patients
From January 2013 to June 2016, patients for the UGI
bleeding who visited the emergency medical center of
the Sanggye Paik Hospital, Seoul, South Korea were
reviewed retrospectively in this study. UGI bleeding was
confirmed by the hospital staff based on the presence of
hematemesis or melena. All patients underwent emer-
gency upper endoscopy within 24 h. Patients with
esophageal or gastric variceal bleeding were excluded.
Cases of iatrogenic post-procedural bleedings after endo-
scopic resection for gastric tumors were also excluded.
The data of the patients were collected in the electronic
medical record. Patients were excluded if the data
required for calculation of relevant risk stratification
scores were unavailable. The data were reviewed by two
endoscopy specialists (M.S.K. and J.C.) for all cases.
Treatment of UGI bleeding
Patients received the same treatment according to
emergency bleeding protocols. All patients received
intravenous proton pump inhibitor infusion before
upper endoscopy. Upper endoscopy was performed
by endoscopy specialists within the first 24 h. Endo-
scopic therapies were applied as following condi-
tions: (1) peptic ulcers with actively bleeding (type
Ia), oozing hemorrhage (type Ib), or a nonbleeding
visible vessel (type IIa); (2) Dieulafoy’s lesion (3)
angiodyplasia (4) and any lesions with active bleed-
ing. Adherent blood clot (type IIb), flat spot (type
IIc), clean base ulcer (type III), or lesions with no
active bleeding stigmata including acute gastric mu-
cosal lesion or Mallory-Weiss tear were initially
treated medication without endoscopic therapy.
Endoscopic therapies included injection of epinephrine,
hemostatic forcep electrocoagulation, argon plasma co-
agulation, or application of endoscopic clips. In cases of
failed endoscopic hemostasis, transarterial embolization
was preferred over surgery. When rebleeding occurred
after successful endoscopic therapy, endoscopic therapy
was initially preferred. Surgery as salvage therapy was per-
formed when embolization was unsuccessful.
Transfusion was required if hemoglobin was below 8
g/dL. ICU admission was considered in the following
conditions: if the patients have any symptoms of confu-
sion or altered mentality; presence of hemodynamic
instability (systolic blood pressure < 90mmHg, need for
vasoactive drugs); or severe comorbid illness including
heart failure, chronic renal failure, liver cirrhosis, or
chronic lung disease. Decision of ICU admission was
made finally by ICU unit attending physicians.
Study design
The following data were collected through electronic
medical record review: age, sex, symptoms of visiting
emergency centers (hematemesis, melena, shock, syncope,
or altered mentality), vital sign (heart rate, systolic blood
pressure), the Glasgow Coma Scale, mental status, medi-
cations that contribute to bleeding (aspirin, clopidogrel,
warfarin, nonsteroidal anti-inflammatory drugs, other
antithrombotic agents). Laboratory findings (hemoglobin,
albumin level, blood urea nitrogen, PT, and INR), and
endoscopic findings were also collected. The AIMS65
score, RS, PRS, and GBS were obtained based on the data.
Components of the each scoring system were described in
Table 1. Primary outcome was in-hospital mortality and
secondary outcomes were composite clinical outcomes of
in-hospital mortality, intensive care unit (ICU) admission;
rebleeding; blood transfusion requirement; and endo-
scopic, radiologic, or surgical intervention.
Statistical analysis
The performance of each scoring system was evaluated
with a receiver operating characteristic (ROC) curve,
calculation of area under the curve (AUC) with 95%
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confidence intervals. In a ROC curve the true positive
rate (sensitivity) is plotted in function of the false posi-
tive rate (100-specificity) for different cut-off points of a
parameter. Each point on the ROC curve represents a
sensitivity/specificity pair corresponding to a particular
decision threshold. The cut-off value of each scoring sys-
tem is determined by the ROC curve with the most spe-
cificity and sensitivity. The risk prediction scoring
system was divided into two groups, high-risk group and
low-risk group. For each scoring systems, a cutoff point
was calculated that maximized the sum of sensitivity and
specificity in predicting the primary and secondary out-
comes. Fischer’s exact test was used for categorical vari-
ables. All confidence intervals are described as two-sided
binomial 95% confidence intervals. The cut-off value
0.05 considered to be the threshold for statistical signifi-
cance. In a Bonferroni correction to adjust for the mul-
tiple comparisons in the scoring systems (in which the P
values were divided by 4 for the comparison with an
alpha level of 0.05), the corrected P values were 0.0125
for the combination group versus. Data were analyzed
using SPSS Statistics for Windows (version 23.0; IBM
Table 1 Components of the AIMS65, full and pre-endoscopic Rockall, and Glasgow-Blatchford scoring system
AIMS65 score Score Rockall score Score
Albumin < 3.0 mg/dL 1 Age
INR > 1.5 1 < 60 yrs 0
Altered mental status, GCS < 14 1 60–79 yrs 1
Systolic BP < 90 mmHg 1 ≥ 80 yrs 2
Age > 65 yrs 1 Shock
Maximum score 5 No shock 0
Pre-endoscopic Rockall Score Pulse > 100 bpm, Systolic BP > 100mmHg 1
Age Systolic BP < 100mmHg 2
< 60 yrs 0 Comorbidity
60–79 yrs 1 No major comorbidity 0
> 80 yrs 2 CHF, IHD, or major comorbidity 2
Shock Renal failure, liver failure, metastatic cancer 3
No shock 0 Diagnosis
Pulse > 100, Systolic BP > 100mmHg 1 Mallory-Weiss tear or no stigmata/lesion 0
Systolic BP < 100mmHg 2 All other diagnoses 1
Comorbidity GI malignancy 2
No major 0 Evidence of bleeding
CHF, IHD, or major comorbidity 2 No stigmata or dark spot on ulcer 0
Renal failure, liver failure, metastatic cancer 3 Blood in UGI tract, adherent clot, visible/spurting vessel 2
Maximum score 7 Maximum score 11
Glasgow-Blatchford score
Blood urea, mmol/L Systolic BP, mm Hg
6.5–8 2 100–109 1
8–10 3 90–99 2
10–25 4 < 90 3
> 25 6 Other risk factors
Hemoglobin, g/dL, Men Pulse (≥100/bpm) 1
12- < 13 1 Melena 1
10- < 12 3 Syncope 1
< 10 6 Liver disease 2
Hemoglobin, g/dL, Women Heart failure 2
10- < 12 1 Maximum score 23
< 10 6
INR International normalized ratio, GCS Glasgow Coma Scale, BP Blood pressure, CHF Congestive heart failure, IHD Ischemic heart disease, bpm beat per minute,
UGI Upper gastrointestinal
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Corp., Armonk, NY, USA). AUCs were compared with
the DeLong method by using MedCalc program (version
16.8.4; MedCalc Software, Mariakerke, Belgium).
Results
Baseline characteristics
A total of 578 patients were enrolled, of which consecu-
tive 512 patients were included in the final analysis. Of
these, 66 patients were excluded from the study for the
following reasons: 30 patients did not have sufficient
data for the study; 16 had iatrogenic post-procedural
bleedings (endoscopic submucosal dissection for gastric
tumors (n = 11), endoscopic mucosal resection (n = 2),
endoscopic sphincterotomy (n = 3)), and 20 patients
were lost to follow-up (Fig. 1).
The median age was 64 (range, 48–80 years) years old,
and 71.9% patients were men. Among patients, 397
(69.7%) patients had comorbidities and 327 (36%) were
taking anti-platelet agents or anti-coagulant medications
on admission. The most common symptom of visiting
the emergency center was melena (27.5%). The common
causes of bleeding were gastric ulcer (32.8%), duodenal
ulcer (20.5%), Mallory-Weiss tear (13.1%), and acute gas-
tric mucosal lesion (12.9%) (Table 2).
Primary clinical outcome: mortality
Seventeen of the 512 patients (3.3%) died. Their median
age was 70.24 (range 43–93) years old. The causes of
death were uncontrolled bleeding (n = 5), complications
due to cirrhosis (n = 5), sepsis due to pneumonia (n = 4),
renal failure (n = 2), and cerebral infarction (n = 1). In
the cases of 5 deaths due to uncontrolled bleeding, two
patients underwent angiographic embolization and two
patients underwent angiography followed by surgery.
One patient died of active duodenal ulcer bleeding and
hypovolemic shock during endoscopic therapy.
All but one of the 17 patients who died had comorbid-
ities. There was no difference between survivors and
non-survivors in the use of anticoagulants. The mortality
increased with increasing AIMS65 score, although death
occurred in 1 patient who scored 0 on the AIMS65.
Mortality was seen in 1/161 (0.6%) for AIMS65 0, 1/
201 (0.5%) for AIMS65 1, 6/104 (5.8%) for AIMS65 2,
6/36 (16.7%) for AIMS65 3, 3/9 (33.3%) for AIMS65
4, 0/1 for AIMS65 5. The AUC values of each test
were: AIMS65 = 0.84 (95% confidence interval (CI),
0.81–0.88), PRS = 0.74 (95% CI, 0.70–0.78), RS = 0.75
(95% CI, 0.71–0.79), and GBS = 0.72 (95% CI, 0.68–
0.76). With regard to AUC value, there was a trend
suggesting that the AIMS65 scoring system (0.84)
seemed more accurate than the GBS system (0.72) for
predicting mortality (P = 0.07) (Table 3) (Fig. 2).
Secondary clinical outcomes
Composite serious clinical outcomes
Of the 512 patients, 134 (26.2%) were diagnosed with
serious clinical outcomes (in-hospital mortality, rebleed-
ing, or ICU admission). For these composite serious
clinical outcomes, the AUC values of AIMS65, PRS, RS,
and GBS were 0.68 (95% CI, 0.64–0.72), 0.70 (95% CI,
0.65–0.74), 0.66 (95% CI, 0.62–0.70), and 0.65 (95% CI,
0.61–0.70), respectively. AUC values of each scoring sys-
tem did not differ significantly in terms of composite
serious clinical outcomes.
Rebleeding
Rebleeding occurred in 65 patients (12.7%). Rebleed-
ing occurred in patients with elderly, or chronic kid-
ney disease. The AUC values for predicted rebleeding
were as follows: AIMS65 = 0.58 (95% CI, 0.54–0.62),
PRS = 0.58 (95% CI, 0.54–0.62), RS = 0.63 (95% CI,
0.59–0.67), and GBS = 0.55 (95% CI, 0.51–0.59). In
pairwise comparisons between the scores for rebleed-
ing, the AUC value of RS was superior to that of PRS
and GBS (pairwise comparison, P = 0.01 and P = 0.04),
but not statistically different than that of AIMS65
(pairwise comparison, P = 0.11).
ICU admission
Eighty-six patients (16.8%) were admitted to the ICU.
The AUC values for predicted admission were:
AIMS65 = 0.73 (95% CI, 0.69–0.77), PRS = 0.70 (95% CI,
0.66–0.74), RS = 0.70 (95% CI, 0.66–0.74), and GBS =
0.71 (95% CI, 0.67–0.75). All four scoring systems simi-
larly predicted the need for ICU admission.
Transfusion requirements
Transfusion was required in 264 patients (62.3%) and
the median transfusion was 2 units (interquartile
range, 0–4). The AUC values for the need of transfu-
sion were: AIMS65 = 0.69 (95% CI, 0.65–0.73), PRS =
0.70 (95% CI, 0.65–0.73), RS = 0.74 (95% CI, 0.70–
0.77), and GBS = 0.87 (95% CI, 0.66–0.74). GBS was
superior to other scoring systems in predicting trans-
fusion requirement.
Fig. 1 Study flow-chart
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Endoscopic intervention
Endoscopic intervention was required in 301 patients
(58.8%). The AUC values for the prediction of the
need of endoscopic intervention were: AIMS65 = 0.57
(95% CI, 0.53–0.62), PRS = 0.56 (95% CI, 0.52–0.61),
RS = 0.56 (95% CI, 0.52–0.61), and GBS = 0.61 (95%
CI, 0.57–0.66) (Table 3).









Diabetes mellitus 78 (15.2)
Cerebrovascular disease 56 (13.2)
Liver disease 47 (9.2)
Chronic renal impairment 40 (7.8)
Ischemic heart disease 30 (5.9)
Malignancy 26 (5.1)
Congestive cardiac failure 19 (3.7)




Nonsteroidal anti-inflammatory drugs 38 (7.4)
Clopidogrel 35 (6.8)
Warfarin 11 (2.1)
Bleeding cause of endoscopic finding;
Gastric ulcer 168 (32.8)
Duodenal ulcer 105 (20.5)
Mallory Weiss tear 67 (13.1)
Acute gastric mucosal lesion 66 (12.9)
Dieulafoy’s lesion 34 (6.6)
Gastrointestinal malignancy 34 (6.6)
Angiodysplasia 21 (4.1)




ICU admission 86 (16.8)
Treatment;
None 211 (41.2)
Argon plasma coagulation 216 (42.2)
Hemostatic forcep coagulation 30 (5.9)
Hemoclipping 55 (10.7)
Epinephrine injection 18 (3.5)
Embolization 7 (14)
Band ligation 1 (0.2)
Mean (95% CI) score;
AIMS65 score 1.1 (0.1–2.1)
Table 2 Baseline characteristics of patients with uppr
gastrointestinal bleeding (Continued)
Characteristics N (%)
Pre-endoscopy Rockall score 3.1 (1.4–4.8)
Full Rockall score 5.6 (4.3–7.8)
Glasgow-Blatchford score 9.6 (5.4–13.6)
Table 3 Comparison of AIMS65, GBS, Pre-endoscopic Rockall
scores (PRS), and Rockall scores (RS) with significant clinical
endpoints
AUC (95% CI) P-value of pairwise the AUC curves
AIMS65 PRS RS GBS
Mortality (n = 17)
AIMS65 0.84 (0.81–0.88) * 0.13 0.01 0.07
PRS 0.74 (0.70–0.78) 0.13 * 0.86 0.74
RS 0.75 (0.71–0.79) 0.09 0.86 * 0.65
GBS 0.72 (0.68–0.76) 0.07 0.74 0.66 *
Serious clinical outcomes (n = 134)
AIMS65 0.68 (0.64–0.72) * 0.54 0.52 0.40
PRS 0.66 (0.62–0.70) 0.53 * 0.05 0.76
RS 0.70 (0.65–0.74) 0.52 0.05 * 0.16
GBS 0.65 (0.61–0.70) 0.40 0.76 0.16 *
Rebleeding (n = 65)
AIMS65 0.58 (0.54–0.62) * 0.97 0.11 0.43
PRS 0.58 (0.54–0.62) 0.97 * 0.01 0.49
RS 0.63 (0.59–0.68) 0.11 0.01 * 0.04
GBS 0.55 (0.51–0.59) 0.43 0.49 0.04 *
ICU admission (n = 86)
AIMS65 0.73 (0.69–0.77) * 0.44 0.39 0.67
PRS 0.70 (0.66–0.74) 0.43 * 0.90 0.78
RS 0.70 (0.66–0.74) 0.39 0.90 * 0.72
GBS 0.71 (0.67–0.75) 0.67 0.78 0.72 *
Transfusion requirement (n = 397)
AIMS65 0.69 (0.65–0.73) * 0.95 0.06 < 0.001
PRS 0.70 (0.65–0.73) 0.95 * 0.01 < 0.001
RS 0.74 (0.70–0.77) 0.06 0.01 * < 0.001
GBS 0.87 (0.84–0.90) < 0.001 < 0.001 < 0.001 *
PRS Preendoscopic Rockall score, RS Rockall score
*Not available
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Cut-off value
The cut-off values for the endpoints of the risk
stratification scores from the AIMS65, PRS, RS, and
GBS were obtained when the cut-off value that max-
imized the sum of the sensitivity and the specificity
was obtained. Sensitivity of AIMS65 was from 41.5%
(CI 19.4–54.4, p < 0.001) to 88.2% (CI 63.6–98.5, p <
0.0001), which was similar to other scoring systems,
ranging from 71.3 (CI 68.1–76.6, p < 0.001) to 78.6
(CI 74.1–82.6, p < 0.001), respectively. Cut-off as a
value separating risk levels (high vs. low risk) for
death was above 2 points on the AIMS65 and 8
points on the GBS, and 1 point on the AIMS65 and
11 points on the GBS for rebleeding. The cut-off
values for ICU admission were 2 points on the
AIMS65, 10 points on the GBS, 4 points on the
PRS, and 5 points on the RS (Table 4).
Discussion
The AIMS65 scoring system was introduced to pre-
dict hospital mortality in patients with UGI bleeding
based on clinical outcomes of bleeding has been val-
idated for use in several studies [11, 15–18]. One
study has found that the AIMS65 score is an inde-
pendent predictor of mortality in patients with UGI
bleeding [16]. One study showed that the accuracy
of AIMS65 score is superior to that of GBS and PRS
in predicting in-hospital mortality [16]. In contrast,
one study showed that PRS is more useful for pre-
dicting mortality than the GBS and AIMS65 scores
[18]. These results might be due to different patient
characteristics and different mortality rate. The mor-
tality rate was 3.3% in our study, compared to 4.2%
in previous study [16], which suggests less severe pa-
tients were included in our study. It is important to
compare the scoring systems within the same popu-
lation and with a similar disease severity [12]. We
conducted the present study in a large number of
patients after excluding patients with variceal bleed-
ing. The risk stratification score was calculated in all
patients using the GBS, the PRS, and the RS. The
AIMS65 showed similar performance to the GBS and
the RS in predicting mortality, rebleeding, ICU ad-
mission, and endoscopic intervention.
The risk stratification scores were recommended
for management of prognosis and serious outcomes
for NVUGI bleeding [19]. In order to be an effective
tool for risk stratification, a measure should be easy
to use and accurately predict bleeding outcomes
[16]. For example, the CHADS2 scoring systems,
which is used to predict cerebral vascular risk in pa-
tients with atrial fibrillation, is widely used because
of its accessibility and simplicity [20]. The GBS scor-
ing system is limited by weighting, which makes
calculation difficult. RS scoring system also has limi-
tations. Weighting leads to complexity in calculation
and it requires endoscopic data for calculation, im-
possible to apply at the time of presentation. Those
systems are much more difficult to apply by the busy clin-
ician in routine clinical practice due to their complexity
[21]. AIMS65 has only 5 components (albumin, INR,
mental status, systolic BP, age) and each component is the
same value of 1 point. The recently-developed AIMS65 is
much easier to apply in clinical practice.
In one study, GBS score 0 identified low-risk patients
who can be managed safely as outpatients [22]. Another
study showed lower-risk patients (GBS score < 12) who
were taken urgently to endoscopy were related to the
worse outcomes [23]. In our study, patients with AIMS65
score 0/1 had low risk of mortality of 0.5%. We believe
that AIMS65 score 0/1 provides a rationale for delaying
emergency endoscopic intervention until the next day
when patients arrive in the evening or night time.
Several studies validated the performance of AIMS65
scoring system to predict the clinical outcomes in patients
with UGI bleeding in Korea. One study showed that
AIMS65 was not useful for predicting the need for endo-
scopic intervention and transfusion in Korea [14]. In this
study, 22% (64/286) patients with variceal bleeding were
included. AIMS65 score showed lower performance than
GBS and RS regardless of variceal or non-variceal bleeding
group. On the other hand, the other study involving 523
patients with NVUIB showed that AIMS65 score was use-
ful for predicting the mortality, transfusion requirement,
and endoscopic intervention in Korean patients with
Fig. 2 Area under the curve (AUC) of each scoring system for risk
stratification scores as predictors of in-hospital mortality. The AIMS65
score (AUC 0.84, 95% CI, 0.81–0.88) seemed to be superior to the
GBS (AUC 0.72, 95% CI, 0.68–0.76) for predicting mortality
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NVUIB [11]. This difference might be due to different pa-
tient characteristics and patient number.
There are limitations in this study. The study
design was retrospective. However, the data were in-
dependently reviewed by two co-authors. We tried to
minimize errors by collecting all medical records for
NVUGI bleeding patients.
Despite the large number of patients included in
this study, mortality occurred in only 17 patients
(3.3%). Each scoring system to predict mortality was
less accurate than previously reported, because death
events were rare [7]. Another limitation of the study
is single center study.
Conclusion
The AIMS65 score in NVUGI bleeding patients was
comparable to the GBS or Rockall scoring systems
when predicting mortality, rebleeding, ICU admission,
and endoscopic intervention in Korean patients. The
AIMS65 score, however, is much easier to calculate
using variables routinely available in the emergency
clinical situation, and has the advantage that it can be
performed by the busy clinician before an endoscopy.
Therefore, we recommend AIMS65 for prediction of
severity of GI bleeding in daily practice. Before the
AIMS65 becomes a standard of care for the risk strati-
fication of UGI bleeding cases, further multicenter
prospective studies will be required.
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Table 4 Cut-off values of each scoring system
Scoring system Cut-off value Sensitivity, % (95% CI) Specificity, % (95% CI) Low risk (%) High risk (%) P-value Odds ratio (95% CI)
AIMS65
Mortality 2 88.2 (63.6–98.5) 72.7 (68.6–76.6) 0.6 10 < 0.001 20.0 (4.5–88.6)
Serious clinical outcomes 2 51.5 (42.7–60.2) 78.6 (74.1–82.6) 18 46 < 0.001 3.8 (2.5–5.9)
Rebleeding 2 41.5 (29.4–54.4) 72.5 (68.1–76.6) 10.5 18 0.02 1.8 (1.1–3.2)
ICU admission 2 62.8 (51.7–73.0) 77.5 (73.2–81.3) 8.8 36 < 0.001 5.8 (3.5–9.5)
Transfusion requirement 1 35.5 (30.8–40.4) 92.2 (85.7–96.4) 62.1 84.6 < 0.001 3.3 (2.1–5.1)
Pre-endoscopic RS
Mortality 4 88.2 (63.6–98.5) 56.4 (51.9–60.8) 0.6 4.8 0.01 3.3 (2.1–5.2)
Serious clinical outcomes 4 63.4 (54.7–71.6) 61.4 (56.3–66.3) 14.4 32.5 < 0.001 2.8 (1.7–4.5)
Rebleeding 3 76.9 (64.8–86.5) 36.9 (32.4–41.6) 8.3 15.1 0.03 1.9 (1.1–3.5)
ICU admission 4 72.1 (61.4–81.2) 60.3 (55.5–65.0) 7.2 22 < 0.001 3.6 (1.9–6.7)
Transfusion requirement 3 71.3 (66.6–75.7) 57.4 (47.8–66.6) 63.3 85.2 < 0.001 3.3 (2.1–5.1)
Rockall Score
Mortality 7 76.5 (50.1–93.2) 67.1 (62.7–71.2) 1.2 7.4 < 0.001 6.6 (2.1–20.6)
Serious clinical outcomes 6 76.1 (68.0–83.1) 54.2 (49.1–59.3) 13.5 37.1 < 0.001 3.7 (2.4–5.9)
Rebleeding 6 72.3 (59.8–82.7) 48.9 (44.3–53.7) 7.6 17.1 < 0.001 2.5 (1.4–4.4)
ICU admission 7 60.5 (49.3–70.8) 70.9 (66.3–75.2) 10.1 29.5 < 0.001 3.7 (2.3–6.0)
Transfusion requirement 5 75.8 (71.3–80.0) 60.8 (51.3–69.8) 57.8 87 < 0.001 4.8 (3.1–7.5)
GBS
Mortality 11 82.4 (56.6–96.2) 53.3 (48.8–57.8) 1.1 5.7 0.01 5.33 (1.5–18.7)
Serious clinical outcomes 10 75.4 (67.2–82.4) 49.5 (44.3–54.6) 15 34.6 < 0.001 3.00 (1.93–4.6)
Rebleeding 10 67.7 (54.9–78.8) 44.5 (39.8–49.3) 9.5 15.1 0.08a 1.6 (0.9–2.9)
ICU admission 11 75.6 (65.1–84.2) 57.8 (52.9–62.5) 7.9 26.5 < 0.001 4.2 (2.4–7.1)
Transfusion requirement 8 82.4 (78.3–86.0) 71.3 (62.1–79.4) 46.1 90.8 < 0.001 11.6 (7.1–18.7)
P-value denotes the Fisher exact test, which was used to compare low and high-risk groups
aDid not reach statistical significance
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